Browsing Category
Pharma Industry News
4750 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
Regencell Bioscience shares surge over 70% amid ADHD, autism hype
Regencell Bioscience stock soared over 70% in a day, extending YTD gains past 6,500%—see what’s driving this biotech’s speculative surge in ADHD and autism.
Aarti Drugs soars with Q4 FY25 profit spike—But what’s behind the full-year revenue drop?
Aarti Drugs Q4 FY25 profit rose 33% YoY as exports rebounded, but full-year revenue declined 5%. See what’s behind the surge—and the challenges ahead.
CStone Pharmaceuticals unveils next-generation ADC pipeline at AACR 2025 as it shifts to proprietary innovation model
CStone Pharmaceuticals reveals powerful preclinical ADC data at AACR 2025, fueling investor interest in its next-gen oncology pipeline and IND filing momentum.
Innovent Biologics advances Phase 2 study of efdamrofusp alfa in diabetic macular edema amid global push for longer-acting therapies
Innovent launches Phase 2 trial of its anti-VEGF-complement fusion protein IBI302 to rival Faricimab in treating diabetic macular edema.
GSK Q1 2025 earnings: Specialty medicines power growth as pipeline builds investor confidence
GSK's Q1 2025 earnings beat forecasts on strong Specialty Medicines growth and pipeline strength—read full results, investor sentiment, and stock outlook.
Nutshell Therapeutics secures FDA IND clearance for NTS071, targeting p53 Y220C mutation in cancer treatment
Find out how Nutshell Therapeutics’ NTS071 is redefining precision oncology by targeting the p53 Y220C mutation with a novel allosteric small molecule.
Sanofi Consumer Healthcare India Q1 FY2025 results: PAT climbs 12.9% post-demerger, stock holds premium valuation
Sanofi Consumer Healthcare India Q1 FY2025 PAT rose 12.9% to â‚ą500 million. Read stock analysis, investor sentiment, and growth outlook post demerger.
Novartis to acquire Regulus Therapeutics in $1.7bn deal to advance farabursen for ADPKD treatment
Novartis to acquire Regulus Therapeutics for $1.7 billion, gaining next-gen kidney drug farabursen for ADPKD. Read the market reaction and deal insights.
AstraZeneca’s $13.6bn Q1 2025 sales surge as cancer drugs and AI deals set stage for $80bn goal
Explore how AstraZeneca’s strong Q1 2025 results, new drug approvals, and AI-powered R&D are reshaping its global growth story.
FILSPARI secures full European approval: A major breakthrough for IgA nephropathy patients
Find out how FILSPARI’s full EU approval marks a major step for IgA nephropathy treatment and strengthens CSL Vifor and Travere Therapeutics’ rare disease focus.